{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-117573","form_type":"8-K","ticker":"RMTI","cik":"0001041024","company_name":"ROCKWELL MEDICAL, INC.","filed_at":"2023-11-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:27.993854+00:00","generated_at":"2026-06-08T03:08:26.109237+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Rockwell Medical Q3 revenue $23.8M, gross profit up 183% YoY; expects adjusted EBITDA profitability in Q4 2023","bullets":["Net sales $23.8M, highest to-date; concentrates sales $21.6M, up 27% YoY.","Operating loss $1.7M, improved 53% YoY; net loss $1.9M vs $4.2M in Q3 2022.","2023 guidance reaffirmed: net sales $82-86M (+17-18% YoY), gross profit $8-10M (+95-144% YoY).","Company now expects adjusted EBITDA profitability in Q4 2023, ahead of prior 2024 target.","Acquired Evoqua hemodialysis concentrates assets; became leading US supplier of liquid bicarbonate."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-117573","json":"https://secwatch.observer/filing/0001104659-23-117573.json","markdown":"https://secwatch.observer/filing/0001104659-23-117573.md","text":"https://secwatch.observer/filing/0001104659-23-117573.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1041024/000110465923117573/0001104659-23-117573-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1041024/000110465923117573/tm2330647d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T03:08:26.109237+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"0d559774acf2e4f7b657376140b9393000e39265","claim":"ROCKWELL MEDICAL, INC. reported the three months ended September 30, 2023 results: revenue $23.8 million. Guidance reaffirmed.","evidence_excerpt":"99.1) --- EX-99.1 2 tm2330647d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Rockwell Medical Announces Third Quarter 2023 Results · Net sales for the third quarter of 2023 were $23.8 million, including concentrates product sales of $21.6 million, both of which were the highest sales generated to-date for the Company. · Gross profit for the third quarter of 2023","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1041024/000110465923117573/0001104659-23-117573-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the three months ended September 30, 2023"},{"label":"Revenue","value":"$23.8 million"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}